Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Umoja BioPharma, Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners, which indicates diversification in the review process for the company's applications. This spread suggests that the company's prosecution strategy must be adaptable to the individual styles and requirements of multiple examiners simultaneously, rather than being concentrated under a single point of contact.
The portfolio spans 3 distinct art units, reflecting a technical breadth within the Biotechnology & Pharmaceuticals sector. The busiest examiner, GOMEZ RODRIGUEZ, JULIO WASHINGTON, is responsible for 1 pending office action. This means that even the most active examiner in the portfolio only handles a single action. Such a distribution across 3 distinct art units and 4 distinct examiners minimizes the impact of any single examiner's tendencies on the overall portfolio. Practitioners should prepare for varied feedback across these 4 pending office actions due to the diverse assignment of examiners and art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262859 | LENTIVIRUS FOR GENERATING CELLS EXPRESSING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 17766654 | RETROVIRAL VECTOR FOR UNIVERSAL RECEPTOR THERAPY | NGUYEN, QUANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037986 | VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF | BATES, KEENAN ALEXANDER | 30d |
| 18262859 | LENTIVIRUS FOR GENERATING CELLS EXPRESSING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 18016307 | GATED ADAPTER TARGETING RECEPTOR | HOWARD, ZACHARY C | — |
| 17766654 | RETROVIRAL VECTOR FOR UNIVERSAL RECEPTOR THERAPY | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1637 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262859 | LENTIVIRUS FOR GENERATING CELLS EXPRESSING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18037986 | VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF | BATES, KEENAN ALEXANDER | 1631 | §102DP | Final Rejection | 30d | Pending | May 19, 2023 |
| 18016307 | GATED ADAPTER TARGETING RECEPTOR | HOWARD, ZACHARY C | 1674 | §112 | Non-Final OA | — | Pending | Jan 13, 2023 |
| 17766654 | RETROVIRAL VECTOR FOR UNIVERSAL RECEPTOR THERAPY | NGUYEN, QUANG | 1631 | §103§112 | Final Rejection | — | Pending | Apr 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial